|
|
The Liver Meeting® October 27 - 31,
2006 |
Welcome to the HCV
Advocate’s AASLD Conference coverage. In
an effort to best serve our readership, we will post all the important and
interesting abstracts about HCV from the conference. While attending the conference, we will
update any abstracts that we personally
cover at the conference. The updated abstracts will be marked with the date
that they have been updated and posted.
The other abstracts posted to the web site are HCV related abstracts
posted to www.aasld.org that we have not
been able to report on or update.
To locate specific
abstracts for each topic below, click on the links.
Please click here
to view our fact sheet on reading and understanding an abstract.
Thank You,
Alan Franciscus
Editor-in-Chief
Hepatitis C
·
Acute
Hepatitis C: Factors that influence spontaneous viral
clearance of hepatitis C.
·
Diagnostic Tools: Various tests to diagnose and manage hepatitis C including various
biochemical marker, imaging, liver biopsy for grading/staging liver disease and
HCV RNA (viral load) tests.
·
Disease Progression: Various factors that influence HCV disease progression including
steatosis, obesity, insulin resistance, diabetes, race/ethnicity, and general
studies on disease progression.
·
Cirrhosis and End Stage Liver
Disease: complications and management of conditions
such as portal hypertension, ascites and encephalopathy.
·
Epidemiology
and Transmission Issues: Studies that look at populations infected
with hepatitis C as well as the transmission risk factors.
·
Experimental Therapies: New treatments for hepatitis C including pre-clinical development that
have not yet been studied in humans, and various drugs that are in phase I, II
and III development to treat hepatitis C.
·
Liver Transplantation: Information on allocation of livers, recurrent HCV after
transplantation, effect of race/ethnicity, immunosuppressant drugs, post
transplant HCV disease progression, and pediatric issues.
·
Current HCV Treatment: FDA approved medications to treat hepatitis C, side effect management,
disease progression after successful treatment, and treatment of various
populations of people with hepatitis C.
·
HIV and Hepatitis C
Coinfection: Disease progression, epidemiology, and
liver transplantation.